AYHAN BALKAN, SEZGIN BARUTÇU, RAMAZAN ERDEM, BUĞRA TOLGA KONDUK, ABDULLAH EMRE YILDIRIM, MURAT TANER
Gaziantep University, Faculty of Medicine, Department of Gastroenterology, Gaziantep, Turkey
Introduction: According to our national health care system previous guidelines, lamivudine (LAM) or telbivudine treatment
should be initiated in the naive chronic hepatitis B (CHB) patients with low viral load. We aimed to investigate the success of LAM
treatment in one year period.
Materials and methods: We retrospectively recruited 125 naive CHB patients on LAM therapy. We recorded biopsy results,
demographic, biochemical, serological and virological values at baseline and 3rd, 6th and 12th months of treatment. Virological response
was defined as undetectable hepatitis B virus (HBV) DNA (<20 IU/mL).
Results: Of patients, 81 were male (65%), and the mean age was 42 ± 13. Mean histological activity index (HAI) was 4.55 ±
2.16, and fibrosis was 2.65 ± 0.90 in 114 patients who had biopsy results. The initial mean HBV DNA level was 5.52 × 106 IU/mL.
Seroconversion was observed in only 3 (18.75%) of 16 HBeAg (+) patients. While baseline median ALT value was 36 U/L, following
values were 28 U/L, 25 U/L and 24 U/L, respectively. HBV DNA significantly and gradually decreased with LAM treatment and it
was finally determined to be negative in 80% of the patients in the 12th month.
Conclusion: LAM treatment for naive CHB patients continues to be effective for the first 6th months, and if continued to be
treated until 12th month, this efficiency can
Efficacy, lamivudine, chronic hepatitis B